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ABSTRACT 
Objective: Okra (Abelmoschus esculentus (L.) Moench) has potential antidiabetic activity. This study created a nanoemulsion of okra extract (NOE) 
and examined its activity on alloxan-induced diabetes mellitus in mice. 
Methods: Okra was macerated with 70% ethanol and dried in a rotary evaporator into the crude extract. The extract was encapsulated in a solution 
of glyceryl caprylate, propylene glycol, and glycerine to form a nanoemulsion. To determine the antihyperglycaemic effect of okra extract, 35 male 
mice (Mus musculus L.) were divided into seven groups: a non-diabetic normal control group and six diabetic mice groups (untreated negative 
control, glibenclamide-treated positive control, and four treatments with okra ethanol extract (OEE) at 200 and 400 mg/kg BW and NOE at 200 and 
400 mg/kg BW). 
Results: The group treated with NOE at 400 mg/kg BW (NOE400) had the lowest average blood glucose level of 93.4 mg/dL among hyperglycaemic 
mice. The decrease in blood glucose levels in NOE400 (52.05%) was significantly different from those in the positive control (42.63%) and OEE 
treatments (39.32%). The nanoemulsion used in this study fulfills quality requirements, with a mean particle size of 134.7 nm, a polydispersity 
index of 0.512, and a zeta value of −26.72 mV. 
Conclusion: NOE reduced blood glucose levels in alloxan-induced hyperglycaemic mice better than OEE. Nanoemulsion can improve the 
antidiabetic activity of okra extract by increasing penetration of active compounds into interstitial space so that their delivery and bioavailability 
are higher.  
Keywords: Abelmoschus esculentus (L.) Moench, Alloxan-induced hyperglycaemic mice, Diabetes mellitus, Nanoparticles, Okra fruit 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i5.37805. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Diabetes mellitus (DM) is a public health problem characterized by 
chronic hyperglycemia and impaired carbohydrate, fat, and protein 
metabolism caused by the dysfunction in insulin secretion, insulin 
action, or both [1]. In long-term damage, DM causes the failure and 
deterioration in the functioning of various organs of the human body 
[2]. In 2010, an estimated 285 million people suffered from DM, and 
this number is expected to increase to 439 million by 2030, with the 
majority of cases emerging in developing countries [3]. DM remains 
a leading cause of mortality and morbidity in the world, although 
various antidiabetic drugs are currently available [2, 4]. 
Okra (Abelmoschus esculentus (L.) Moench) is a functional food. It is 
used in traditional medicine for its phytochemical compounds that 
have many pharmacological activities [5]. Previous studies have 
found that some compounds in this plant have antidiabetic and 
antihyperglycaemic activity [6]. Okra is rich in dietary fibers with 
natural hypoglycaemic action that can lower blood sugar levels by 
limiting the rate of sugar absorption in the intestinal vili [7]. 
According to Anjani et al., diabetic rats given okra extract showed a 
significant reduction in blood glucose levels [8].  
Nanoparticle technology has grown rapidly in the last few years and 
has been widely applied for medicine due to the role of nanomaterial 
in different biomedical applications [9]. Nanoparticles are microscopic 
and excellent for increasing the bioavailability of biomolecules because 
of their diffusion ability and better penetration into the mucus layer 
[10]. The use of okra fruit as an antidiabetic agent can be improved by 
forming nanoemulsions with fruit extracts.  
In a previous study, we showed that a nanoemulsion of okra fruit at 
pharmaceutical dosage had higher therapeutic effectiveness as an 
anticholesterol agent than a crude extract [11]. This study is aimed 
at determining the effects of an ethanol extract of okra fruit (OEE) 
and nanoemulsion of okra fruit extract (NOE) on alloxan-induced 
DM in mice. 
MATERIALS AND METHODS 
Samples 
Okra Fruit was obtained from the Indonesian Spice and Medicinal 
Crops Research Institute (BALITRO) at Bogor, West Java, Indonesia. 
Okra has the taxonomic plant identification number 
591/IPH.1.01/lf.07/III/2018 at the Herbarium Bogoriense, 
Botanical Division, Research Center for Biology, Indonesian Institute 
of Sciences (LIPI) Bogor.  
Chemicals and reagents  
Sodium hydroxide (≥99.0% purity), ammonium hydroxide, sodium 
acetate, chloroform (purity>99%), hydrogen chloride (37%, 
analytical grade), amyl alcohol (99.8%, analytical grade), ferric 
chloride (97%, reagent grade), ether, acid acetate anhydride 
(pharmaceutical secondary standard), hydrogen sulphate (99.99%, 
analytical grade), magnesium powder (turnings powder, 98%, 
reagent grade), ethanol (pure, d=0.789 g/ml), aquadest, propylene 
glycol, capmul and glycerine (99.5% purity) were purchased from 
Merck Indonesia Company. Mayer’s reagents, dragendorff’s reagent, 
and Stiasny reagent (formalin 30%, concentrated HCl 1/0.5) were 
obtained from Q-Lab Faculty of Pharmacy, Pancasila University. 
Extraction of okra fruit  
The okra fruit was extracted with 70% ethanol with kinetic 
maceration and dried in a rotary vacuum evaporator into a crude 
extract according to the method described by Ratna Djamil et al. 
(2020) [11]. 
Phytochemical screening 
Phytochemical screening was performed according to Materia 
Medika Indonesia (1995) and Farnsworth’s methods [12, 13]. 
Qualitative phytochemistry tests were conducted to analyze 
secondary metabolites, such as alkaloids, flavonoids, saponins, 
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tannins, quinones, steroids/terpenoids, coumarins, and volatile 
compounds.  
Preparation of the nanoemulsion of okra fruit extract (NOE) 
The NOE was prepared by the cosolvent method according to the 
method described by Ratna Djamil et al. (2020) [11]. A 100-mg 
crude extract of okra fruit was dissolved in a cosolvent consisting of 
1:2.5:2:10 (v/v) capmul (glyceryl caprylate), propylene glycol, 
glycerine, and aqua dest. The mixture was homogenized by shaking 
gently to obtain an emulsion of nanoparticles. The stability of the 
nanoparticle emulsion was then observed for five days; this included 
observation of color, turbidity, and sediment. 
Evaluation of the nanoemulsion of okra fruit extract  
The size, distribution, and zeta potential of NOE particles were 
measured using a particle size analyzer (DelsaNano™, Beckman 
Coulter, Brea, CA, USA). The morphology of nanoparticles was 
evaluated with transmission electron microscopy (TEM; JEOL 1010, 
JEOL Ltd., Tokyo, Japan). 
Ethical approval 
Ethical approval to conduct the study was granted by the Health 
Research Ethics Committee, Faculty of Medicine, Universitas 
Indonesia-Cipto Mangunkusumo Hospital Jakarta Indonesia (No. 
KET-772/UN.2. FI/ETIK/PPM.00.02/2019), with protocol number 
19-07-0825. 
Experimental design of antidiabetic activity in vivo 
The mice were acclimated to laboratory conditions for a week before 
behavioral monitoring, under conditions of 12 h light-dark cycle, 
70%±2 relative humidity, and a temperature of 22±2 °C. Thirty-five 
male mice were divided into seven groups of five mice each. The 
normal control group (Group 1) consisted of non-diabetic mice. For 
the induction of hyperglycemia, mice in the diabetic groups were 
intraperitoneally injected (i. p.) with alloxan at a concentration of 
200 mg/kg body weight (BW). The hyperglycaemic mice were 
divided into six equal groups of five animals each: an untreated 
group as a negative control (Group 2); a group treated with 0.62 
mg/kg BW of glibenclamide as a positive control (Group 3); two 
groups that received OEE, one at a dose of 200 mg/kg BW (Group 4) 
and the other at 400 mg/kg BW (Group 5); and two groups that 
received NOE, one at a dose of 200 mg/kg BW (Group 6) and the 
other at 400 mg/kg BW (Group 7). Glibenclamide, OEE, and NOE 
were administered orally for 14 d.  
Measurement of fasting blood glucose (FBG) levels and body 
weight (BW) 
There were two stages to this experiment; in the first induction 
phase, mice were induced with alloxan at 200 mg/kg BW i. p., while 
in the second treatment phase, mice with hyperglycemia were 
administered different treatments as described above. BW and 
fasting blood glucose (FBG) levels were measured to assess the 
overall condition of the mice. The mice fasted for approximately 16 h 
each time before measuring blood glucose levels. Mouse blood was 
taken from the tail and measured using a glucometer. The data were 
then statistically analyzed using ANOVA. 
RESULTS AND DISCUSSION 
Phytochemical screening 
The results of the qualitative phytochemistry tests for flavonoids, 
steroids, triterpenoids, coumarins, and saponins of the dried okra 
fruit and OEE are shown in table 1. The phytochemical content of 
okra fruit that we obtained was similar to that reported by Islam 
(2019). Fresh okra fruit is rich in pectin and mucilage, protein, fat, 
minerals, carbohydrate, flavonoids, and some important vitamins. 
Ethanolic extracts of okra fruit contain carbohydrates, gums and 
mucilage, proteins, phytosterols, flavonoids, tannins, phenolic 
compounds, volatile oils, and triterpenoids [14]. 
  
Table 1: Phytochemical screening of dried okra fruit and OEE 
Phytochemical compound Dried okra fruit OEE 
Alkaloid + + 
Flavonoid + + 
Saponin + + 
Quinone - - 
Tannins - - 
Steroids + + 
Triterpenoids + + 
Volatile oil - - 
Coumarine + + 
Note.+: detected,-: No detected 
 
Evaluation of the nanoemulsion of okra extract  
The droplets of NOE appeared dark and spherical and were more or 
less 100 nm in size. TEM confirmed that the nanoparticles were 
homogenously spherical with an average size of about 134.7+2 nm 
(fig. 1). The results of our morphological analysis are similar to those 
for a cationic nanoemulsion of indomethacin for ophthalmic delivery 
studied by Ajmeera et al. [15]. The polydispersity index of the 
particle size distribution, which reflects the polydispersity of the 
emulsion, ranged from 0 to 1. Lower polydispersity index values 
indicate a more monodispersed suspension. The NOE has a 
polydispersity index of 0.512; an index value<0.5 indicates a 
relatively homogeneous dispersion. The zeta potential of NOE was 
−26.72 mV. The okra fruit nanoemulsion formulation has a negative 
zeta potential due to the anionic fractions of the ingredients. 
Nanoparticles with a zeta potential greater than+30 mV or less than 
−30 mV are considered strongly cationic and strongly anionic, 
respectively [16]. The zeta potential value shows that the particles in 
the NOE are stable because the electric charge of the droplets is 
strong enough to repel the droplets dominant in the nanoemulsion 
suspension system. High zeta potential is considered the cause of 
lower aggregation of particles. The charge on the nanoparticle 
surface will affect its distribution in the body and increase the 
uptake of nanoparticles into cells [17]. 
The phytochemicals in OEE contain beneficial antihyperglycaemic 
compounds that may be developed into commercially rewarding 
modern formulations of traditional medicine. However, in their 
natural form, they possess certain undesirable characteristics that 
can be remedied by encapsulation into nanoemulsions. The 
characterization of NOE in our study may be of use in the further 
development of useful tools and/or products with okra fruit extract. 
Bodyweight analysis 
The changes in BW from day 0 to 14 are shown for the different 
treatment groups in table 1. The data are presented as the 
mean±standard deviation for each group of five mice. The BW of the 
diabetic mice began decreasing three days after hyperglycemia was 
induced with alloxan. This loss in BW was the result of a reduction in 
the formation of fats and proteins, which can be broken down into 
energy [18]. BW then increased after 14 d of treatment. Overall, the 
treatments reduced BW loss in diabetic mice. Diabetic mice treated 
with NOE experienced lower BW reductions compared to the other 
treatments. The reduction in BW of diabetic mice treated with OEE 
was close to that of the glibenclamide-treated group (positive 
control). In our study, the administration of treatments to diabetic 
 
 
 Mice body weight average (gram
Animal group Day 0 
Normal control 22.28+0.33 
Negative control 22.08+0.50 
Positive control 22.30+0.32 
OEE 200 21.88+0.79 
OEE 400 22.38+0.79 
NOE 200 22.70+0.51 
NOE 400 22.52+0.59 
Note: The data was written in mean±SD from 5 mice
 
Changes in fasting blood glucose levels 
The changes in FBG levels in the animals are shown in 
development of diabetic conditions was evaluated on the third day 
after alloxan injection. All diabetic mouse groups developed DM, as is 
shown by their higher FBG levels compared to the non
(normal control). The mice in the normal control had an average 
  
Fig. 2: The changes in FBG levels in normal condition
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mice affected BW, demonstrating that it triggered the formation of 
fat, which is generally the main cause of BW gain 
treatment with OEE, NOE, or glibenclamide was shown to increase 
BW in diabetic mice compared to untreated diabetic mice.
Fig. 1: The morphology of NOE 
Table 2: Mice body weight average 
+SD) 
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The FBG level of the negative control (untreated diabetic mice) 
increased to 189+3.08 mg/dl on day 3, with only a slight decrease to 
180.0+5.10 mg/dl on day 7 and 172.6+4.98 mg/dl on day 14. The 
FBG levels decreased from day 3 to day 14 in all diabetic mice in the 
positive control and all OEE and NOE treatment groups. The FBG 
level of the positive control was 179.2+8.87 mg/dl on day 3; then, 
after treatment with glibenclamide, the FBG levels decreased to 
146.0+8.51 and 102.8+5.07 mg/dl on days 7 and 14, respectively. 
Glibenclamide is an antihyperglycaemic agent effective in lowering 
blood glucose levels. The FBG levels of hyperglycaemic diabetic mice 
decreased after treatment with OEE and NOE. On day 14, the FBG 
levels decreased significantly to 93.4+1.14 until 117+5.79 mg/dl. 
NOE at 400 mg/kg BW showed the highest reduction in FBG levels 
among all treatments. Diabetic mice treated with OEE at 200 and 
400 mg/kg BW had FBG levels almost the same as the 
glibenclamide-treated positive-control diabetic mice. This suggests 
that OEE and NOE can increase insulin secretion by pancreatic β 
cells to a similar extent to glibenclamide. 
 
Table 3: Mice FBG measurement 
Group Mice FBG levels (mg/dl) Percentage of decrease 
FBG levels (%) Day 3 Day 7 Day 14 
Normal control  97.0+4.00*#  97.8+2.90*#  98.6+2.51*# -1.65 
Negative control 189.0+3.08 180.0+5.10# 172.6+4.98# 8.68 
Positive control 179.2+8.87 146.0+8.51* 102.8+5.07* 42.63 
OEE200 192.8+3.70 165.8+2.59*# 117.0+5.79*# 39.32 
OEE400 192.0+5.10 159.6+5.13*#  99.4+8.02* 48.23 
NOE200 193.8+6.87 164.6+10.5*#  96.2+1.30*# 50.36 
NOE400 194.8+5.45 154.4+8.02*  93.4+1.14*# 52.05 
Note: The data were presented as mean±SD from 5 experiments, * significantly different compared to the negative control, #significantly different 
compared to the positive control. OEE200: Okra extract ethanol at dose 200 mg/kg BW, OEE400: Okra extract ethanol at dose 400 mg/kg BW, 
NOE200: Nanoemulsion okra extract ethanol at dose 200 mg/kg BW, NOE400: Nanoemulsion okra extract ethanol at dose 400 mg/kg BW. p<0.05, n 
= 5 mice/group. 
 
Table 3 shows that all diabetic mouse groups were given 
glibenclamide or OEE and NOE at doses of 200 and 400 mg/kg BW had 
decreased FBG levels from day 7. This was a statistically significant 
result compared to the negative control group. Until day 14 of 
treatment, all groups of diabetic mice experienced a significant 
decrease in FBG levels compared to the negative control group. This 
means that OEE and NOE at all doses have the potential to reduce FBG 
levels. The FBG levels at day 7 in the group receiving NOE at 400 
mg/kg BW were not statistically significant from that of the 
glibenclamide group. This means that NOE at this dose has the 
potential to reduce blood glucose levels as well as glibenclamide does. 
On day 14, the FBG levels in groups receiving NOE at doses 200 and 
400 mg/kg BW were significantly different compared to that of the 
glibenclamide group. NOE appears to have better activity than 
glibenclamide due to the higher percentage decrease in FBG levels in 
the groups receiving it. The percentage decrease in FBG levels from the 
highest to the lowest order was NOE 400>NOE 200>OEE 400>positive 
control>OEE 200. Based on the percentage decrease in FBG levels, 
NOE at 400 mg/kg BW has the highest blood-glucose-reducing activity. 
OEE at a dose of 400 mg/kg BW was the most similar in activity to 
glibenclamide. In addition, NOE was more effective at decreasing 
FBG levels than OEE. This demonstrates that the nano emulsification 
of OEE could improve its activity. This study confirms that okra fruit 
has hypoglycaemic activity. It may thus be a useful alternative 
medicine to treat different kinds of DM [21]. Nanoparticle 
encapsulation has been reported to increase the bioavailability of 
active compounds in plant extracts [22, 23]. Therefore, 
nanoencapsulation can improve the pharmacological activity of 
active compounds in okra fruits. 
CONCLUSION 
Oral administration of okra fruit could reduce blood glucose levels of 
mice with alloxan-induced hyperglycemia. A nanoemulsion of okra 
extract reduced the FBG levels of diabetic mice better than the standard 
extract. The nanoemulsion of okra, formed by mixing propylene glycol, 
capmul, and glycerine, could enhance the antidiabetic activity of okra 
fruit. The nanoemulsion contained spherical particles 134.7 nm in size 
with a zeta potential of −26.72 mV. The nanoemulsion at a dose of 400 
mg/kg BW was the most potent antidiabetic agent among all the types 
examined in this study. Nanoemulsion of okra fruit may be suggested as 
an effective herbal therapy for diabetes. 
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